Cargando…

The use and safety risk of repurposed drugs for COVID-19 patients: lessons learned utilizing the Food and Drug Administration’s Adverse Event Reporting System

OBJECTIVES: This study was designed to assess the disproportionality analyses of adverse drug reactions (ADRs) related to hydroxychloroquine and remdesivir and how ADR reporting fluctuated during the COVID-19 pandemic. METHODS: A retrospective observational study was conducted utilizing the Food and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alsuhaibani, Deemah S., Edrees, Heba H., Alshammari, Thamir M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232922/ https://www.ncbi.nlm.nih.gov/pubmed/37304358 http://dx.doi.org/10.1016/j.jsps.2023.05.023

Ejemplares similares

Completeness of adverse drug reactions reports of the Saudi adverse event reporting system
por: Alshammari, Thamir M., et al.
Publicado: (2015)

Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system
por: Zhang, Ying, et al.
Publicado: (2023)

Drug safety: The concept, inception and its importance in patients’ health
por: Alshammari, Thamir M.
Publicado: (2016)

Cosmetics and Cancer: Adverse Event Reports Submitted to the Food and Drug Administration
por: Jacob, Saya L, et al.
Publicado: (2018)

1380. Safety of Repurposed Drugs for Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: An Analysis of Adverse Events Reported in the Literature
por: Stone, Heather, et al.
Publicado: (2019)

Prevention of adverse events in the administration of drugs
por: Diano, G, et al.
Publicado: (2010)

Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities
por: Walker, Venexia M, et al.
Publicado: (2017)

Mortality and oral anticoagulants in the Food and Drug Administration Adverse Event Reporting System
por: Serebruany, Victor, et al.
Publicado: (2017)

Safety signals of albumin-bound paclitaxel: Data mining of the Food and Drug Administration adverse event reporting system
por: Wang, Yuwei, et al.
Publicado: (2023)

The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2022)

Drug-induced tooth discoloration: An analysis of the US food and drug administration adverse event reporting system
por: Wang, Jun, et al.
Publicado: (2023)

Automatically Recognizing Medication and Adverse Event Information From Food and Drug Administration’s Adverse Event Reporting System Narratives
por: Polepalli Ramesh, Balaji, et al.
Publicado: (2014)

Safety Profile of Levonorgestrel: A Disproportionality Analysis of Food and Drug Administration Adverse Event Reporting System (Faers) Database
por: Kurian, Anitha, et al.
Publicado: (2018)

Aspirin in the Food and Drug Administration Adverse Event Reporting System: Missing Demographics and Underreporting
por: Serebruany, Victor L., et al.
Publicado: (2017)

Coronavirus disease 2019 in Saudi Arabia: A nationwide real-world characterization study
por: Alenzi, Khalidah A., et al.
Publicado: (2022)

Spontaneous Reporting on Adverse Events by Consumers in the United States: An Analysis of the Food and Drug Administration Adverse Event Reporting System Database
por: Toki, Tadashi, et al.
Publicado: (2018)

Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration’s Adverse Event Reporting System, 2010-2017
por: Dores, Graça M., et al.
Publicado: (2019)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
por: Liang, Yankun, et al.
Publicado: (2023)

Adverse drug event risk assessment by the virtual addition of COVID‐19 repurposed drugs to Medicare and commercially insured patients’ drug regimens: A drug safety simulation study
por: Smith, Matt K., et al.
Publicado: (2021)

Pharmacovigilance-based drug repurposing: searching for putative drugs with hypohidrosis or anhidrosis adverse events for use against hyperhidrosis
por: Liu, Yi, et al.
Publicado: (2023)

Reporting adverse drug events to the Therapeutic Goods Administration
por: Martin, Jennifer H, et al.
Publicado: (2021)

Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports
por: Kato, Yamato, et al.
Publicado: (2015)

Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system
por: Cross, Raymond K., et al.
Publicado: (2019)

Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)
por: Vestergaard Kvist, Annika, et al.
Publicado: (2021)

Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the food and drug administration adverse event reporting system
por: Wei, Wei, et al.
Publicado: (2023)

Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database
por: Nagai, Junko, et al.
Publicado: (2021)

Retrospective analysis of adverse events with spironolactone in females reported to the United States Food and Drug Administration
por: Wang, Yu, et al.
Publicado: (2020)

Retrospective analysis of dermatologic adverse events associated with hydroxychloroquine reported to the US Food and Drug Administration
por: Lipner, Shari R., et al.
Publicado: (2020)

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
por: Bonora, Benedetta Maria, et al.
Publicado: (2021)

PSAT122 The Changing Face of Drug-Induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
por: Dalmazi, Guido D, et al.
Publicado: (2022)

Liver injury in children: signal analysis of suspected drugs based on the food and drug administration adverse event reporting system
por: Liu, Yan, et al.
Publicado: (2023)

Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis
por: Zhou, Zeyun, et al.
Publicado: (2020)

Psoriasis adverse events and associated medications as reported in the US Food and Drug Administration’s Adverse Event Reporting System from 2016 to 2021
por: Learned, Christine, et al.
Publicado: (2022)

Vaccine adverse event reporting system (VAERS): Evaluation of 31 years of reports and pandemics’ impact
por: Almadani, Ohoud A., et al.
Publicado: (2022)

Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy
por: Al Rihani, Sweilem B., et al.
Publicado: (2020)

Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System
por: Naganuma, Misa, et al.
Publicado: (2019)

Adverse Events Associated with Use of Digoxin Immune Fab Reported to the US Food and Drug Administration Adverse Event Reporting System, 1986–2019
por: Wei, Shaokui, et al.
Publicado: (2021)

Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system
por: Wu, Ziyang, et al.
Publicado: (2022)

Comparison of the safety information on drug labels in three developed countries: The USA, UK and Canada
por: Alshammari, Thamir M., et al.
Publicado: (2017)

Detecting associations between behavioral addictions and dopamine agonists in the Food & Drug Administration’s Adverse Event database
por: Gendreau, Katherine E., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_hbiibpdqpfm60kmno0dc4e35vu